Posterior fossa ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes (Part I of ependymomas across compartments)

• by George W. Koutsouras, Francisco Rivera, Anthony M. Price, Derek S. Tsang, Adam Esbenshade, Vijay Ramaswamy, Peter B. Dirks, Michael C. Dewan

• September 22, 2026

Comparing the utility of FDG PET-CT and contrast-enhanced CT in patients with oesophagogastric adenocarcinoma treated with neoadjuvant chemotherapy

• by J. L. Moore, M. Arora, C. Sit, R. Rahman, M. Green, H. Deere, J. Lagergren, S. Chicklore, F. Chinaka, N. Maisey, S. Ngan, A. Sita-Lumsden, A. Qureshi, K. Owczarczyk, W. R. C. Knight, M. Kelly, C. R. Baker, J. A. Gossage, M. Subesinghe, A. R. Davies

• September 17, 2026

Safety-Oriented Benchmarking of Large Language Models in Risk-Based Management of Abnormal Cervical Screening Results: Scenario-Based Benchmark Study

• by Ömer Osman Eroğlu, Cansın Eroğlu

• September 22, 2026

Dana-Farber/Boston Children's Named the Top Pediatric Cancer Program in the Nation for 2026-2027

U.S. News & World Report has recognized Dana-Farber/Boston Children’s Cancer and Blood Disorders Center as the #1 pediatric cancer program in the nation in its 2026-2027 Best Children’s Hospitals report.

• by

• September 15, 2026

• 3 min